Phosphodiesterase-5 Inhibition in Diastolic Heart Failure: The RELAX Trial Rationale and Design

Heart failure (HF) with preserved ejection fraction (HFpEF) or “diastolic HF” accounts for approximately half of HF cases. To date, neurohumoral antagonists have failed to show a significant benefit on clinical outcomes in HFpEF. While our understanding of the pathophysiology of HFpEF continues to d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Redfield, MM, Borlaug, BA, Lewis, GD, Mohammed, SF, Semigran, MJ, LeWinter, MM, Deswal, A, Hernandez, AF, Lee, KL, Braunwald, E
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3530955/
https://ncbi.nlm.nih.gov/pubmed/22991405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.969071
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars